Full Press Release Details
Technologies Announces Pricing of $4.8 Million Public Offering
ANTONIO, TX - September 29, 2025 - bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW)
a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has
priced a public offering of securities as described below for aggregate gross proceeds to the Company of $4.8 million, before deducting
agent fees and other estimated expenses payable by the company.
offering consists of 1,921,799 shares (the "Shares") of our Common Stock (or pre-funded warrants (the "Pre-Funded Warrants")
in lieu thereof) at a purchase price of $2.50 per share (or $2.493 per Pre-Funded Warrant). Each Pre-Funded Warrant will be exercisable
for one share of our Common Stock and will be immediately exercisable and will expire when exercised in full. The purchase price of each
Pre-Funded Warrant will equal the price per share of Common Stock being sold to the public, minus $0.007, and the exercise price of each
Pre-Funded Warrant will be $0.007 per share.
closing of the offering is expected to occur on or about September 30, 2025, subject to the satisfaction of customary closing
Capital, LLC is acting as sole placement agent for the offering.
press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of such jurisdiction.
securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-290480), as
amended, previously filed and declared effective by the Securities and Exchange Commission (SEC). This press release
shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the
securities laws of any such state or jurisdiction. The offering is being made only by means of a preliminary prospectus and final prospectus
that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will
be available on the SEC's website at www.sec.gov. Electronic copies of the prospectus supplements may be obtained, when available,
from WallachBeth Capital, LLC, via email at cap-mkts@wallachbeth.com, by calling +1 (646) 237-8585, or by standard mail at WallachBeth
Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.
bioAffinity Technologies, Inc.
Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum
cancer treatments. The Company's first product, CyPath Lung, is a noninvasive test that has shown high sensitivity,
specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT)
by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws.
Words such as "may," "might," "will," "should," "believe," "expect,"
"anticipate," "estimate," "continue," "predict," "forecast," "project,"
"plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are
forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements
regarding the closing of the offering. These forward-looking statements are subject to various risks and uncertainties,
many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions
from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially
from current expectations include, among others, the ability to close the offering when anticipated and the risk factors discussed in
the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including
subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at
the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking
statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements.
The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to
update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities